Newsfeeds Archive - Spark Newswire

1 minute read

Actinium Presents Oral Presentation Featuring Improved Outcomes In TP53 Patients Receiving Iomab-B In The Phase 3 SIERRA Trial At EHA 2024 Annual Congress

June 14, 8:41 AM

- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard

ATNM

1 minute read

Actinium Highlights Mutation Data From The Phase 3 SIERRA Trial Of Iomab-B And Novel Linker Technology To Support Solid Tumor Antibody Radiation Conjugate Development At The 2024 SNMMI Annual Meeting

By Benzinga Newsdesk

June 10, 8:37 AM

Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutationIomab-B safely delivered radiation to the target bone

ATNM

2 minute read

Actinium Announces KOL Webinar To Highlight Recently Announced Iomab-ACT Trial With Leading FDA Approved Commercial CAR T-Cell Therapy Being Led By The University Of Texas Southwestern

By Benzinga Newsdesk

May 7, 8:21 AM

Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Investigator for the trial to join Actinium management for webinarExpansion of Iomab-ACT program

ATNM

2 minute read

Actinium Highlights Ability Of Iomab-B To Overcome High-Risk TP53 Mutation Resulting In Improvement In Overall Survival In Patients With Active Relapsed Refractory AML At The European Bone Marrow Transplant Annual Meeting

By Benzinga Newsdesk

April 18, 8:11 AM

-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active relapsed or

ATNM

2 minute read

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit In High-Risk Relapsed Or Refractory Acute Myeloid Leukemia Patients With TP53 Mutations Accepted For Oral Presentation At The European Bone Marrow Transplant Annual…

By Benzinga Newsdesk

April 1, 8:09 AM

- The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis- Represents the

ATNM

1 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

February 9, 5:31 PM

Gainers Singular Genomics Sys (NASDAQ:OMIC) shares moved upwards by 17.9% to $0.66 during Friday’s after-market session. The market…

ATNM

37 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

October 3, 2:37 PM

On Tuesday, 647 companies set new 52-week lows.

AADI

3 minute read

Actinium Pharma Presents Survival Data From Extended Follow-Up From Actimab-A + CLAG-M Trial And Preclinical Data Supporting Program Expansion With FLT3 Inhibitor Combinations At SOHO

By Happy Mohamed

September 7, 8:48 AM

- Extended follow-up in the Actimab-A + CLAG-M trial showed median overall survival in patients proceeding to bone marrow transplant of 24 months in all patients and 30 months in patients who received prior

ATNM

13 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 6, 2023

By Benzinga Insights

September 6, 11:00 AM

Upgrades According to Morgan Stanley, the prior rating for First Solar Inc (NASDAQ:FSLR) was changed from Underweight to…

AAL

2 minute read

Actinium Pharma Highlights Six Abstracts Accepted For Oral And Poster Presentation At The SNMMI 2023 Annual Meeting

By Benzinga Newsdesk

June 23, 8:05 AM

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details the six abstracts accepted for oral and poster presentation at the upcoming

ATNM